See more : Ionic Rare Earths Limited (IXR.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Todos Medical Ltd. (TOMDF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Todos Medical Ltd., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Pure Biologics Spólka Akcyjna (PUR.WA) Income Statement Analysis – Financial Results
- Fujian Foxit Software Development Joint Stock Co.,Ltd (688095.SS) Income Statement Analysis – Financial Results
- Sinic Holdings (Group) Company Limited (2103.HK) Income Statement Analysis – Financial Results
- Tesla, Inc. (TL0.DE) Income Statement Analysis – Financial Results
- Harbour Digital Asset Capital Limited (0913.HK) Income Statement Analysis – Financial Results
Todos Medical Ltd. (TOMDF)
About Todos Medical Ltd.
Todos Medical Ltd., a vitro diagnostics company, develops and commercializes blood tests for the detection of cancer and Alzheimer disease in the United States. The company develops Total Biochemical Infrared Analysis, a proprietary cancer-screening technology using peripheral blood spectroscopy analysis for examination into cancer's influence on the immune system; Lymphocyte Proliferation Test, a diagnostic blood test that determines the ability of peripheral blood lymphocytes and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle; and blood tests for the detection of neurodegenerative disorders, such as Alzheimer's disease. Its cancer screening and diagnosis products include TM-B1 and TM-B2 for breast cancer tests; and TMC blood test for the screening and diagnosis of colon cancer. The company also offers Tollovid, a 3CL protease inhibitor dietary supplement to support healthy immune function against circulating coronaviruses; and Tollovir, an antiviral treatment for Covid-19 that is in Phase 2 clinical trial. Todos Medical Ltd. has a collaboration agreement with Integrated Health LLC, as well as has agreements with various companies to develop screening tests for SARS-nCoV-2; and to distribute certain COVID-19 test kits. Todos Medical Ltd. was incorporated in 2010 and is headquartered in Tel Aviv, Israel.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.70M | 12.23M | 5.21M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 3.39M | 7.85M | 3.82M | 29.64K | 25.65K | 24.08K | 20.70K | 11.90K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 4.31M | 4.38M | 1.39M | -29.64K | -25.65K | -24.08K | -20.70K | -11.90K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 56.01% | 35.84% | 26.68% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 620.00K | 824.00K | 9.86M | 755.70K | 459.18K | 720.53K | 317.91K | 374.02K | 336.47K | 377.31K | 312.17 |
| General & Administrative | 0.00 | 9.36M | 5.79M | 2.76M | 919.69K | 617.09K | 410.98K | 456.96K | 64.37K | 34.51K | 22.06 |
| Selling & Marketing | 0.00 | 3.48M | -3.06M | -667.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.44M | 12.85M | 5.79M | 2.76M | 919.69K | 617.09K | 410.98K | 456.96K | 64.37K | 34.51K | 22.06 |
| Other Expenses | 0.00 | 0.00 | -53.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 14.06M | 13.67M | 15.65M | 3.52M | 1.38M | 1.34M | 728.89K | 830.98K | 400.85K | 381.82K | 256.12 |
| Cost & Expenses | 17.44M | 21.52M | 19.47M | 3.52M | 1.38M | 1.34M | 728.89K | 830.98K | 400.85K | 381.82K | 256.12 |
| Interest Income | 0.00 | 28.61K | 13.37K | 959.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||
| Interest Expense | 14.85M | 28.61M | 3.83M | 958.74K | 75.43K | 12.44K | 78.78K | 0.00 | 0.00 | ||
| Depreciation & Amortization | 750.00K | 763.00K | 96.00K | 29.64K | 25.65K | 24.08K | 20.70K | 11.90K | 434.00 | 275.00 | 0.28 |
| EBITDA | -9.39M | -9.72M | -14.17M | -7.78M | -1.35M | -1.31M | -708.19K | -819.08K | -400.41K | -339.26K | -244.22 |
| EBITDA Ratio | -122.08% | -59.33% | -465.70% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.75M | -9.29M | -14.26M | -3.52M | -1.38M | -1.34M | -728.89K | -830.98K | -400.85K | -339.53K | -244.49 |
| Operating Income Ratio | -126.68% | -75.93% | -273.88% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -15.23M | -34.03M | -15.51M | -8.30M | 921.34K | -1.34M | 75.43K | 12.44K | 78.78K | -42.29K | -11.63 |
| Income Before Tax | -24.98M | -43.31M | -29.77M | -11.81M | -457.54K | -2.68M | -653.46K | -818.54K | -322.07K | -381.82K | -256.12 |
| Income Before Tax Ratio | -324.64% | -354.16% | -571.79% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 13.00K | 31.61M | 2.63M | -2.01M | 871.34K | -2.68M | 0.00 | 0.00 | 0.00 | -38.18K | -25.37 |
| Net Income | -24.99M | -74.92M | -32.40M | -9.81M | -457.54K | -2.68M | -653.46K | -818.54K | -322.07K | -343.64K | -230.75 |
| Net Income Ratio | -324.81% | -612.60% | -622.32% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.02 | -0.11 | -0.13 | -0.11 | -0.01 | -0.04 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.02 | -0.11 | -0.13 | -0.11 | -0.01 | -0.04 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Weighted Avg Shares Out | 1.43B | 679.57M | 259.18M | 92.02M | 70.87M | 68.59M | 76.74M | 62.47M | 28.45M | 27.00M | 24.90K |
| Weighted Avg Shares Out (Dil) | 1.43B | 679.57M | 259.18M | 92.02M | 70.87M | 68.59M | 76.74M | 62.47M | 28.45M | 27.00M | 24.90K |
Todos Medical Announces Positive Observational Trial Results for Oral Antiviral 3CL Protease (MPro) Inhibitor Tollovir®
Todos Medical Announces October Conference Calendar
Todos Medical receives Amazon's approval to sell immune supplements Tollovid and Tollovid Daily
Todos Medical Receives Approval by Amazon to Sell Immune Supplements Tollovid® & Tollovid Daily™
Todos Medical sees 2Q revenue rocket to $1.7M, driven by sales from its coronavirus distribution business
Todos Medical Reports Second Quarter 2021 Financial Results
UPDATE: Todos Medical Announces 90-Day Moratorium on Conversions of Convertible Notes and Lockup of Common Stock Sales with Convertible Note Holders
Todos Medical launches Tollovid Daily via subscription model
Todos Medical Launches Tollovid Daily™ via Subscription at MyTollovid.com
Todos Medical Receives Trademark Notice of Allowance from USPTO for Its 3CL Protease Inhibitor Oral Antiviral Drug Candidate Tollovir™
Source: https://incomestatements.info
Category: Stock Reports